Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (2) 2
aged (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
male (2) 2
middle aged (2) 2
adolescent (1) 1
adult; aged; anemia; antiviral agents; asthenia; cohort studies; dose-response relationship, drug; drug therapy, combination; female; hepacivirus; hepatitis c, chronic; host-pathogen interactions; humans; interferon-alpha; male; middle aged; neutropenia; outcome assessment; polyethylene glycols; proportional hazards models; rna, viral; recombinant proteins; ribavirin; withholding treatment; medicine (1) 1
analysis (1) 1
anemia - chemically induced (1) 1
antiviral agents (1) 1
antiviral agents - adverse effects (1) 1
antiviral agents - therapeutic use (1) 1
asthenia - chemically induced (1) 1
biology and life sciences (1) 1
biopsies (1) 1
body mass (1) 1
body mass index (1) 1
body size (1) 1
care and treatment (1) 1
chronic infection (1) 1
clinical medicine (1) 1
cohort studies (1) 1
digestive system diseases (1) 1
dose-response relationship, drug (1) 1
double-blind method (1) 1
drug therapy, combination (1) 1
enrollments (1) 1
ethics (1) 1
fatty liver - drug therapy (1) 1
fatty liver-disease (1) 1
gastroenterology (1) 1
gastroenterology & hepatology (1) 1
genotype & phenotype (1) 1
genotypes (1) 1
hematology (1) 1
hepacivirus - drug effects (1) 1
hepacivirus - genetics (1) 1
hepacivirus - physiology (1) 1
hepatitis (1) 1
hepatitis c (1) 1
hepatitis c virus (1) 1
hepatitis c, chronic - drug therapy (1) 1
hepatitis c, chronic - virology (1) 1
hepatology (1) 1
histology (1) 1
host-pathogen interactions - drug effects (1) 1
impact analysis (1) 1
infections (1) 1
influence (1) 1
interferon (1) 1
interferon-alpha - adverse effects (1) 1
interferon-alpha - therapeutic use (1) 1
laboratories (1) 1
liver cirrhosis (1) 1
lung diseases (1) 1
medical services (1) 1
medicine and health sciences (1) 1
multidisciplinary sciences (1) 1
necrosis-factor-alpha (1) 1
neutropenia - chemically induced (1) 1
outcome assessment - methods (1) 1
outcome assessment - statistics & numerical data (1) 1
patients (1) 1
peginterferon alpha2a plus ribavirin adultanemiaarticleastheniabody masscaucasiancontrolled studydrug dose reductiondrug efficacydrug responsedrug safetydrug withdrawalfemalehepatitis chepatitis c virus genotype 1hepatitis c virus genotype 2hepatitis c virus genotype 3hepatitis c virus genotype 4humanmajor clinical studymaleneutropenianeutrophil countprognosisside effectthrombocyte countthrombocytopeniatreatment durationtreatment outcomeweight reduction (1) 1
pioglitazone (1) 1
polyethylene glycols - adverse effects (1) 1
polyethylene glycols - therapeutic use (1) 1
primary biliary-cirrhosis (1) 1
proportional hazards models (1) 1
receptors (1) 1
recombinant proteins - adverse effects (1) 1
recombinant proteins - therapeutic use (1) 1
research (1) 1
research and analysis methods (1) 1
ribavirin (1) 1
ribavirin - adverse effects (1) 1
ribavirin - therapeutic use (1) 1
ribonucleic acid (1) 1
ribonucleic acid--rna (1) 1
risk (1) 1
rna (1) 1
rna, viral - blood (1) 1
rna, viral - genetics (1) 1
safety (1) 1
severity (1) 1
ursodeoxycholic acid - administration & dosage (1) 1
virus diseases (1) 1
viruses (1) 1
vitamin-e (1) 1
withholding treatment (1) 1
young adult (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial
by Leuschner, Ulrich F. H and Lindenthal, Birgit and Herrmann, Günter and Arnold, Joachim C and Rössle, Martin and Cordes, Hans‐Jörg and Zeuzem, Stefan and Hein, Jasper and Berg, Thomas and NASH Study Grp and NASH Study Group and the NASH Study Group
Hepatology, ISSN 0270-9139, 08/2010, Volume 52, Issue 2, pp. 472 - 479
In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial... 
VITAMIN-E | PIOGLITAZONE | FATTY LIVER-DISEASE | PRIMARY BILIARY-CIRRHOSIS | RISK | NECROSIS-FACTOR-ALPHA | RECEPTORS | GASTROENTEROLOGY & HEPATOLOGY | BIOPSIES | SEVERITY | Young Adult | Ursodeoxycholic Acid - administration & dosage | Double-Blind Method | Humans | Middle Aged | Adolescent | Adult | Female | Male | Aged | Fatty Liver - drug therapy | Liver cirrhosis | Histology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort
by Foster, Graham R and Coppola, Carmine and Derbala, Moutaz and Ferenci, Peter and Orlandini, Alessandra and Reddy, K. Rajender and Tallarico, Ludovico and Shiffman, Mitchell L and Ahlers, Silke and Bakalos, Georgios and Hassanein, Tarek and Basho, Jovan and Shabanaj, Gentian and Harxhi, Arjan and Debzi, Nabil and Afredj, Nawel and Guessab, Nawal and Mahindad, Nadir and Mahiou, Hassene and Aissaoui, Magda and Al Qameesh, Jihad and Al Ghandoor, Zuhal and Assene, Collins and Bastens, Boris and Brixko, Christian and Cool, Mike and De Galocsy, Chantal and Delwaide, Jean and George, Christophe and Laukens, Pierre and Lefebvre, Veronique and Mulkay, Jean-Pierre and Nevens, Frederik and Servais, Benoit and Van Vlierberghe, Hans and Horsmans, Yves and Henrion, Jean and Sprengers, Dirk and Michielsen, Peter and Bourgeois, Stefan and Lasser, Luc and Langlet, Philippe and Robaeys, Geert and Martinet, Jean-Paul and Warzee, Philippe and Hoste, Paul and Reynaert, Hendrik and Juriens, Irène and Decaestecker, Jochen and Van Der Meersch, Filip and Janssens, Filip and Ahmetagic, Sead and Verhaz, Antonija and Bevanda, Milenko and Calkic, Lejla and Ibrahimpasic, Nevzeta and Mesihovic, Rusmir and Mello, Carlos Eduardo and Ruiz, Fernando Jose and Junior, Elson Martins and Ferraz, Maria Lucia and Silva, Giovanni and Mendes, Claudio and Lyra, Andre and Silva, Mariliza Henrique and Gomide, Geisa and Fernandes, Julio Cesar and Pereira, Patricia and Correa, Maria Cassia and Teixeira, Rosangela and Yousry, Ayman and Hanno, Abdelfatah and Gabr, Mamdouh and Omar, Ashraf and Esmat, Gamal and Karatapanis, Stilianos and Nikolopoulou, Vassiliki and Giannoulis, Grigoris and Manolakopoulos, Spilios and Elefsiniotis, Ioannis and Drakoulis, Christos and Dimitroulopoulos, Dimitrios and Kanatakis, Stilianos and Ketikoglou, Ioannis and Mimidis, Konstantinos and Evgenidis, Nikolaos and Akriviades, Euaggelos and Vafiadi-Zoubouli, Irini and Tsianos, Epameinondas and Mela, Maria and Orfanou, Eleni and Mousoulis, Georgios and Karagiannis, Ioannis and Manesis, Emmanuel and Varga, Marta and Nemesánszky, Elemér and Fried, Katalin and Schuller, János and Szalay, Ferenc and Lengyel, Gabriella and ... and GUARD-C Study Grp and GUARD-C Study Group
PLoS ONE, ISSN 1932-6203, 03/2016, Volume 11, Issue 3, p. e0151703
Background Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains... 
MULTIDISCIPLINARY SCIENCES | Outcome Assessment (Health Care) - methods | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Host-Pathogen Interactions - drug effects | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Dose-Response Relationship, Drug | RNA, Viral - genetics | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Neutropenia - chemically induced | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Proportional Hazards Models | Anemia - chemically induced | Hepatitis C, Chronic - drug therapy | Withholding Treatment | Asthenia - chemically induced | Outcome Assessment (Health Care) - statistics & numerical data | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Cohort Studies | Influence | Care and treatment | Interferon | Research | Hepatitis C | Analysis | Laboratories | Medical services | Chronic infection | Viruses | Infections | Ribavirin | Impact analysis | Hepatitis | Ethics | Body mass index | Genotype & phenotype | Hepatology | Gastroenterology | Safety | Genotypes | Antiviral agents | Hematology | Enrollments | Lung diseases | Ribonucleic acid--RNA | Patients | Body mass | Body size | Clinical medicine | Hepatitis C virus | RNA | Ribonucleic acid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.